Chemotherapy drugs through nanoencapsulation and innovative new drug candidates
Total Trials
2
As Lead Sponsor
As Collaborator
0
Total Enrollment
70
NCT06332092
FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma
Phase: Phase 2
Role: Lead Sponsor
Start: Apr 10, 2024
Completion: Dec 31, 2025
NCT06694480
Study of FID-022 in Participants With Advanced Solid Tumors
Phase: Phase 1
Start: Jul 3, 2025
Completion: Jun 30, 2028
Loading map...